5-Pyrimidinecarboxamide, 4-[[(1R)-1,2-dimethylpropyl]amino]-2-[[4-[(methylsulfonyl)oxy]phenyl]amino]-

JAK3-IN-9 (compound 11i) (Female Lewis rats; 3, 10 and 30 mg/kg; Oral gavage once daily for 20 days) can selectively inhibit JAK3 cytokine signaling in the primary cells^[1]. JAK3-IN-9 (Male DBA1j of 8 to 12-weeks old mice; 1mg/kg, Intravenous injection, Single administration) shows high AUC of 2104 μg/ml, extends t_1/2 to 2.56 h and good oral bioavailability of 48%^[1]. JAK3-IN-9 (30 mg/kg; Oral gavage once daily for 20 days) suppress paw swelling in a dose-dependent manner with ED₅₀ value of 10 mg/kg^[1].